Aldeyra Therapeutics, Inc. (ALDX) Analysts See $-0.32 EPS

March 14, 2018 - By Richard Conner

 Aldeyra Therapeutics, Inc. (ALDX) Analysts See $ 0.32 EPS
Investors sentiment increased to 3.13 in Q3 2017. Its up 1.46, from 1.67 in 2017Q2. It improved, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 5 reduced holdings. 11 funds opened positions while 14 raised stakes. 18.26 million shares or 145.50% more from 7.44 million shares in 2017Q2 were reported.
Barclays Pcl accumulated 3,400 shares. Bancorp Of Mellon Corporation holds 0% or 18,570 shares. Alphaone Inv Svcs Limited Liability Com invested in 725 shares or 0% of the stock. Jane Street Grp Ltd reported 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Tower Rech Cap Ltd Company (Trc) reported 3,183 shares. Fmr Ltd holds 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 1.61M shares. Knoll Mngmt Lp has invested 0.76% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Royal Retail Bank Of Canada holds 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) or 9 shares. Ardsley Advisory Prtnrs invested 0.04% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Blackrock Inc holds 0% or 37,667 shares in its portfolio. 50,000 were reported by Weiss Multi. Hikari Power Limited holds 0.1% or 107,858 shares. 683 Cap Limited Liability Company owns 835,514 shares. Adage Capital Grp Inc Limited Co owns 750,000 shares for 0.01% of their portfolio. Millennium Lc owns 545,085 shares for 0.01% of their portfolio.

Since September 19, 2017, it had 1 insider purchase, and 0 selling transactions for $1.45 million activity.

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.32 EPS on March, 29.They anticipate $0.04 EPS change or 11.11 % from last quarter’s $-0.36 EPS. After having $-0.32 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see 0.00 % EPS growth. It closed at $8.85 lastly. It is down 18.94% since March 15, 2017 and is downtrending. It has underperformed by 35.64% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. Cowen & Co maintained the stock with “Buy” rating in Thursday, September 14 report. Cowen & Co maintained the stock with “Buy” rating in Wednesday, August 9 report. Cowen & Co initiated the shares of ALDX in report on Tuesday, September 8 with “Outperform” rating. The firm has “Buy” rating given on Wednesday, September 13 by Canaccord Genuity. As per Thursday, June 15, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Monday, September 26. Stifel Nicolaus initiated Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on Friday, July 1 with “Buy” rating. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) earned “Buy” rating by Cantor Fitzgerald on Tuesday, October 24. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, August 9. The firm earned “Buy” rating on Thursday, November 9 by Cantor Fitzgerald.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $169.19 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

More notable recent Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) news were published by: which released: “A Second Chance To Get In On Aldeyra Therapeutics” on September 19, 2017, also with their article: “What’s Next For Aldeyra Therapeutics?” published on February 02, 2018, published: “Aldeyra Therapeutics’ stock soars after positive results of dry eye disease …” on September 12, 2017. More interesting news about Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) were released by: and their article: “Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common …” published on September 21, 2017 as well as‘s news article titled: “Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye …” with publication date: February 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.